Chondroprotective Effect of Kartogenin on CD44-Mediated Functions in Articular Cartilage and Chondrocytes by Ono, Yohei et al.
Cartilage
2014, Vol. 5(3) 172 –180
© The Author(s) 2014






One of the early events associated with osteoarthritis is the 
pronounced loss of aggrecan from the cartilage.1 The gly-
cosaminoglycan hyaluronan (HA) is also depleted in tan-
dem with the loss of aggrecan.2-8 Aggrecan turnover occurs 
within the extracellular environment because of the activity 
of endoproteinases termed aggrecanases as well as matrix 
metalloproteinases.9,10 The aggrecanases ADAMTS4 and 
ADAMTS5 are thought to be the key mediators of aggrecan 
loss.11-14 Our work has focused on the fate of the remaining 
portion of the aggrecan aggregate namely, the HA and 
HA-bound aggrecan-G1 domains terminating with 
ITEGE373 and DIPEN341; sequences that are generated fol-
lowing cleavage of aggrecan via aggrecanases or matrix 
metalloproteinases respectively. Our previous studies have 
demonstrated that HA and bound G1-ITEGE proteins 
undergo co-endocytosis by articular chondrocytes, medi-
ated via the HA receptor, CD44.15,16
Hyaluronan–CD44 interactions are also the primary 
means for the retention of aggrecan to the cell surface of 
chondrocytes.17,18 Since HA serves as the core filament of 
the cartilage proteoglycan aggregate, we hypothesize that 
the enhancement of HA levels is necessary for chondro-
cytes to undergo successful cartilage repair such as repair 
episodes during the early stages of osteoarthritis. 
Extracellular HA is regulated by the activity of hyaluronan 
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Abstract
Objective: A recent report identified the small molecule kartogenin as a chondrogenic and chondroprotective agent. Since 
changes in hyaluronan metabolism occur during cartilage degeneration in osteoarthritis, we began studies to determine 
whether there was a connection between extracellular hyaluronan, CD44–hyaluronan interactions and the effects of 
kartogenin on articular chondrocytes. Methods: Chondrocytes cultured in monolayers, bioengineered neocartilages, 
or cartilage explants were treated with kartogenin with or without stimulation by IL-1β. Accumulation of matrix was 
visualized by a particle exclusion assay or by safranin O staining and release of sulfated glycosaminoglycans was determined. 
Production of aggrecanases and aggrecan G1-ITEGE neoepitope, fragmentation of CD44 and the SMAD1/5/8 signaling 
pathway were evaluated by western blotting. Results: Kartogenin treatment enhanced chondrocyte pericellular matrix 
assembly and retention in the presence of IL-1β. The chondroprotective effects of kartogenin on IL-1β-induced release 
of sulfated glycosaminoglycans from articular cartilage explants, reduction in safranin O staining of neocartilage discs 
as well as a reduction in aggrecan G1-ITEGE neoepitope in chondrocyte and explant cartilage cultures were observed. 
Kartogenin partially blocked the IL-1β-induced increased expression of ADAMTS-5. Additionally, kartogenin-treated 
articular chondrocytes exhibited a decrease in CD44 proteolytic fragmentation. However, kartogenin treatment did not 
enhance proteoglycan in control, non-IL-1β-treated cultures. Similarly, kartogenin enhanced the SMAD1 phosphorylation 
but only following pretreatment with IL-1β. Conclusion: These studies provide novel information on the chondroprotective 
function of kartogenin in adult articular cartilage. The effects of kartogenin are significant after activation of chondrocytic 
chondrolysis, which may occur following disruption of homeostasis maintained by hyaluronan–CD44 interactions.
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synthases (HAS)19 and, the local catabolism of hyaluronan 
by CD44 receptor-mediated endocytosis.16
A recent report identified the small molecule kartogenin 
as a chondrogenic and chondroprotective agent.20 The ele-
vated release of nitric oxide by bovine articular chondro-
cytes and the release of sulfated glycosaminoglycans from 
bovine cartilage explants, induced by oncostatin M and 
TNFα, were significantly reduced on treatment with karto-
genin. Also, intra-articular injection of kartogenin reduced 
tibial plateau cartilage degeneration in the mouse osteoar-
thritis models. This molecule, kartogenin, is expected to be 
a possible novel therapeutic drug for the treatment of osteo-
arthritis.21 However, there has not yet been any other pub-
lished report of kartogenin. Since changes in HA metabolism 
occur during cartilage degeneration in osteoarthritis, we 
began studies to determine whether kartogenin exhibited 
chondroprotective properties in our system. For example, 
we determined whether kartogenin affected the retention of 
HA-dependent pericellular matrices as well as other CD44–
HA interactions that are necessary for the maintenance of 
articular chondrocytes. In this study, the effects of karto-
genin on primary chondrocytes in monolayer cultures, in 
bioengineered neocartilages, and in cartilage explants, were 
examined with or without prestimulation with IL-1β.
Materials and Methods
Chondrocyte and Cartilage Explant Culture
Primary articular chondrocytes were isolated from the 
metacarpophalangeal joints of 18- to 24-month-old adult 
steers and from human osteoarthritis knee cartilage follow-
ing joint replacement within 24 hours after surgery. The 
acquisition of human cartilage was approved by the 
Institutional Review Board of East Carolina University. 
Chondrocytes were liberated from full thickness slices of 
articular cartilage by sequential pronase/collagenase diges-
tion.22 Primary bovine and human chondrocytes were cul-
tured in a DMEM/Ham’s F-12 (Corning Cellgro, Manassas, 
VA) medium containing 10% fetal bovine serum (FBS, 
Hyclone, South Logan, UT) and 50 units/mL penicillin, 
l-glutamate, and ascorbic acid. The chondrocytes were 
plated either as high-density monolayers (1.0 × 106 cells/
cm2) for immediate analysis, as low-density monolayers 
(5,000 cells/cm2) for particle exclusion assay analysis, or 
cultured in alginate beads as described previously23 for sub-
sequent placement into bioengineered neocartilage disks. 
Chondrocytes released from alginate beads were allowed to 
form neocartilage by an additional 2 weeks in culture in 
0.4-µm pore membrane cell culture inserts (Becton 
Dickinson, Franklin Lakes, NJ) as described previously.23 
In other experiments, full-thickness cartilage disks were 
made using a 6-mm biopsy core punch from either bovine 
articular cartilage or from a relatively intact region on the 
femoral condyle from an osteoarthritis patient (72 years old, 
male) and cultured as tissue explants.
Treatment of Cells and Explants
Primary chondrocytes in monolayer or alginate beads, neo-
cartilages or cartilage explants were treated for varying 
time periods with 1.0 or 10.0 ng/mL IL-1β (R&D Systems, 
Minneapolis, MN) in serum-free culture medium in the 
presence or absence of 0.1 to 100.0 µM kartogenin (Cellagen 
Technology, San Diego, CA). Dimethylsulfoxide (DMSO) 
was always used as the carrier control for kartogenin. For 
analysis of BMP signaling, chondrocytes were treated with 
100 ng/mL BMP724 (R&D Systems, Minneapolis, MN) or 
with 10 µM kartogenin.
Particle Exclusion Assay
Particle exclusion assay was performed as described previ-
ously.25 Briefly, after treatment with IL-1β, kartogenin or 
both, the media of low-density monolayer bovine chondro-
cytes was replaced with a suspension of formalin-fixed 
erythrocytes in serum free media. Additionally, the live cells 
were labeled with calcein AM (Sigma-Aldrich, St. Louis, 
MO) to delineate the plasma membrane. Cells were photo-
graphed using a Nikon TE2000 inverted phase-contrast 
fluorescence microscope. The presence of cell-bound extra-
cellular matrix was seen as a particle-excluded zone sur-
rounding the chondrocytes. Treatment with 100 units/mL 
testicular hyaluronidase (Sigma-Aldrich) for 1 hour removed 
the hyaluronan-dependent pericellular coat, whereupon the 
particles abutted the plasma membrane.
Histology
After IL-1β and, with or without kartogenin treatment, 
bovine neocartilage disks were fixed with 4% buffered 
paraformaldehyde overnight at 4 °C, rinsed in 30% sucrose, 
phosphate-buffered saline, and embedded in OCT-freezing 
medium. Cryostat sections (10 µm) were prepared and 
stained with safranin O for the detection of proteoglycans 
and counterstained with Fast Green.
Determination of Sulfated Glycosaminoglycan 
Release
Bovine cartilage explants were pretreated in serum free cul-
ture medium in the presence or absence of 100 µM karto-
genin for 48 hours, and treated with or without IL-1β  
(10 ng/mL). The medium samples were collected after 
24 hours, and equal volumes were analyzed for sulfated 
glycosaminoglycans. Shark chondroitin sulfate (Sigma) 
dissolved at a concentration of 0 to 500 µg/mL in culture 
174 Cartilage 5(3)
medium was used to produce a standard curve. Twenty 
microliters of media were added to a 96-well plate, fol-
lowed by 180 µL of dimethylmethylene blue (DMMB) 
reagent. After 5 minutes of incubation, absorbance was 
determined at 525 nm with a Multiskan Ascent microplate 
reader. The sulfated glycosaminoglycans content was then 
calculated from the standard curve.26,27
SDS-PAGE and Western Blotting
For monolayer cultures, cell lysates were prepared using Cell 
Lysis Buffer (Cell Signaling, Danvers, MA) containing 
Protease Inhibitor Cocktail (Thermo Scientific, Rockford, 
IL). For each sample, 20 µg total protein or, an equal volume 
of 20-fold concentrated media, was loaded and separated on 
Novex 4% to 12% gradient sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS-PAGE) gels (Invitrogen, 
Grand Island, NY). After electroblot transfer onto nitrocellu-
lose membranes and blocking in 5% nonfat dry milk, mem-
branes were incubated with primary antibodies followed by 
horse radis peroxidase–conjugated secondary antibodies. 
Detection was performed using chemiluminescence (Novex 
ECL; Invitrogen). Specific antibodies used for analysis were 
rabbit affinity-purified anti-CD44 cytoplasmic tail antisera 
(1:5,000) (cytotail antibody),28,29 rabbit anti-ITEGE373 (0.5 
µg/mL, generously provided by Dr. Amanda Fosang),16,30,31 
goat anti-ADAMTS4 (1:1,000, Santa Cruz Biotechnology, 
Dallas, TX),32 rabbit anti-ADAMTS5 (1:2,000, Thermo 
Fisher, Rockford, IL),32 rabbit anti-SMAD1 (1:1,000, 
Invitrogen),33 rabbit anti-phosphorylated-SMAD1/SMAD5/
SMAD8 (1:1,000, Cell Signaling),33 and mouse anti-β-actin 
(1:10,000, Sigma-Aldrich).
For explant cultures, the cartilage discs were quick fro-
zen with dry ice and ground to a powder in a stainless steel 
chamber and direct protein extracts were prepared using 
RIPA buffer (Rockland, Gilbertsville, PA) and Protease 
Inhibitor Cocktail, followed by the same procedure 
described above.
Real-Time Reverse Transcription–Polymerase 
Chain Reaction
Total RNA was isolated from chondrocyte cultures with 
TRIzol reagent (Invitrogen), according to the manufacturer’s 
instructions. The RNA was reverse transcribed with qScript 
cDNA Supermix reagents (Quanta BioSciences, Gaithersburg, 
MD) and amplified at 42 °C for 30 minutes. For real-time 
reverse transcription–polymerase chain reaction (RT-PCR), 
the PCR products were detected using RT2 Real-Time SYBR 
Green reagents (SABiosciences, Frederick, MD). Primer-
specific amplification was performed at 60 °C for 30 sec-
onds. However, fluorescence quantification was performed at 
a higher temperature (72°C). The primers pair sequences for 
bovine genes, forward and reverse, are as follows; GAPDH, 
5′-ATTCTGGCAAAGTGGACATCGTCG-3′, 5′-ATGGCC 
TTTCCATTGATGACGAGC-3′; ADAMTS4, 5′-TCACTG 
ACTTCCTAGACAATGG-3′, 5′-ACTGGCGGTCAGCGT 
CGTAGT-3′; ADAMTS5, 5′-CACCGTGGCTCACGAAA 
TTG-3′, 5′-GGAGCCGAAATTTTCTTCACAGA-3′. All 
primers were obtained from Integrated DNA Technologies 
(Coralville, IA). Thermal cycling and fluorescence detection 
were performed using the SmartCycler System (Cepheid). 
Real-time PCR efficiencies and the fold increase in copy 
numbers of messenger RNA (mRNA) were calculated as 
described previously.34 The data are presented as mean ± 
standard deviation (SD) by setting negative control as 1.0, 
and analyzed by Student’s t test. P values <0.05 were consid-
ered significant.
Results
Kartogenin Blocks IL-1β-Mediated Loss of 
Pericellular Coat Retention on Bovine Articular 
Chondrocytes
To examine potential effects of kartogenin on cell-associ-
ated pericellular matrices (coats), a particle exclusion assay 
was used on live bovine articular chondrocytes cultured in 
monolayer. As shown in Figure 1A and 1B, kartogenin 
treatment alone did not significantly enhance chondrocyte 
pericellular coat size. However, the typically observed loss 
of pericellular coats due to IL-1β treatment (Fig. 1C) was 
blocked by co-incubation with kartogenin and IL-1β (Fig. 
1D). To determine whether kartogenin was affecting bio-
synthesis and/or assembly of the pericellular coats, karto-
genin was added during the regrowth phase, the phase 
following treatment for 1 hour with 100 units/mL testicular 
hyaluronidase to remove the HA-rich coats. In control 
chondrocytes, a small coat was reestablished within 24 
hours (Fig. 1E). However, in the presence of kartogenin a 
more robust recovery of the pericellular matrix was 
observed (Fig. 1F) albeit not as pronounced as the recovery 
observed in Figure 1D. This suggests that kartogenin may 
be affecting HA-dependent matrix assembly at multiple 
levels, in part by promoting synthesis and/or assembly of 
pericellular matrices.
Kartogenin Blocks IL-1β-Mediated Loss of 
Proteoglycan Retention within Neocartilage and 
Articular Cartilage
We use bioengineered neocartilages as softer, more manipu-
latable models of intact adult cartilage. Neocartilages are 
typically more cellular, rich in HA (and aggrecan) and as 
such, share similarity to newborn cartilage. A typical, control 
neocartilage disk is shown in Figure 1G, wherein the tissue 
exhibited strong safranin O staining indicative of a HA/pro-
teoglycan-rich extracellular matrix. As with the cell coats, 
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kartogenin treatment alone (Fig. 1H) did not significantly 
enhance the safranin O staining as compared to control neo-
cartilages (Fig. 1G). IL-1β treatment of neocartilage disks 
resulted in a loss of safranin O staining (Fig. 1I) as expected. 
The loss of safranin O staining was blocked with co-treat-
ment of the neocartilage with kartogenin and IL-1β (Fig. 1J).
Full-thickness cartilage discs from bovine articular carti-
lage cultured as explants exhibited enhanced release of sul-
fated glycosaminoglycans on IL-1β treatment, as expected, 
as determined by DMMB analysis26,27 of the media. This 
release of sulfated glycosaminoglycans was significantly 
reduced with co-treatment of the articular cartilage with 
kartogenin and IL-1β (Fig. 2).
Kartogenin Treatment Reduces IL-1β Stimulation 
of the Release of G1-ITEGE and ADAMTS5 into 
the Media of Chondrocyte Cultures
To examine the effects of kartogenin on catabolism of 
aggrecan, human (Fig. 3A) and bovine (Fig. 3B) chondro-
cyte monolayer cultures were treated with IL-1β in the pres-
ence or absence of kartogenin, the media were collected and 
processed for Western blot analysis with the anti-ITEGE, 
anti-ADAMTS4 and anti-ADAMTS5 antibodies; 3 repre-
sentative markers of aggrecanolysis. Little to no G1-ITEGE 
was observed in the medium unless the chondrocytes were 
first treated with IL-1β (Fig. 3A and 3B). The enhanced 
Figure 1. Kartogenin blocks IL-1β-mediated loss of pericellular coat retention on articular chondrocytes as well as loss of proteoglycan 
retention within neocartilage. Pericellular matrices (coats) were examined on bovine articular chondrocytes cultured in monolayer. 
Green cells represent live cells labeled with calcein-AM (A-F) and those shown are representative of 2 independent experiments. 
Chondrocytes were treated with 10 ng/mL IL-1β in the presence or absence of 10 µM kartogenin for 48 hours. Kartogenin treatment 
alone (B) did not significantly enhance coat size seen on untreated chondrocytes (A). However, the loss of coats due to IL-1β treatment 
(C) was blocked by co-incubation with kartogenin and IL-1β (D). If cells were pretreated with testicular hyaluronidase for 1 hour (E), 
subsequent kartogenin treatment promoted the recovery of coats (F). Insets in panels A-F depict low power views of each condition. 
(G-J) Bovine neocartilages were treated with 10 ng/mL IL-1β in the presence or absence of 100 µM kartogenin for 48 hours. Kartogenin 
treatment alone (H) did not change safranin O staining, as compared with untreated neocartilages (G); however, the loss of safranin O 
staining induced by IL-1β treatment (I) was inhibited by co-treatment with kartogenin (J).
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release of G1-ITEGE was inhibited in cultures co-treated 
with kartogenin and IL-1β (Fig. 3A and 3B). Similarly, 
increases in ADAMTS4 and ADAMTS5 (the proteinases 
that generate G1-ITEGE) were observed only following 
IL-1β treatment (Fig. 3B). Again, co-incubation of karto-
genin with IL-1β blocked the stimulated release of 
ADAMTS5, and ADAMTS4 to a lesser extent (Fig. 2B). 
Under the same conditions, the mRNA expression of 
ADAMTS5 in bovine chondrocytes was elevated following 
pretreatment with IL-1β (Fig. 2C) and, this increase was 
blunted by the co-incubation of kartogenin with IL-1β (Fig. 
3C). G1-ITEGE accumulation in human osteoarthritic car-
tilage explants was also examined (Fig. 4B). In the case of 
these cartilage explants from osteoarthritic patients, no pre-
activation with IL-1β was required to observe G1-ITEGE 
epitope by western blot analysis of detergent extracts of the 
cartilage. Several weeks of treatment of the human osteoar-
thritic cartilage explants with kartogenin substantially 
inhibited the accumulation of the G1-ITEGE domains.
Kartogenin Decreased CD44 Fragmentation in 
Bovine Articular Chondrocytes and in Long-Term 
Cultured Human Cartilage Explants
The receptor CD44 plays a critical role in the retention and 
anchoring of HA and aggrecan. We have shown previously 
that in association with osteoarthritis, CD44 is cleaved or 
shed from the surface of chondrocytes leaving the 18 to 20 kD 
Figure 2. Kartogenin treatment reduces IL-1β stimulation of 
proteoglycan release from articular cartilage explant cultures. 
Bovine articular cartilage disks were cultured as explants in 
serum free media the in the absence (−) or presence (+) of 
100 µM kartogenin (KGN) for 48 hours and then treated and 
treated without (−) or with (+) 10 ng/mL IL-1β for 24 hours. 
The medium samples were collected and analyzed for sulfated 
glycosaminoglycans. Data from 6 replicate disks (experiment A) and 
from 8 replicate disks (experiment B) show that KGN treatment 
alone did not change the release of sulfated glycosaminoglycans 
from the cartilage explants while IL-1β treatment did; however, 
the enhanced release of sulfated glycosaminoglycans was inhibited 
by co-treatment with KGN and IL-1β. (A, n = 6, P = 0.060; B, 
n = 8, P = 0.010.)
Figure 3. Kartogenin treatment reduces IL-1β stimulation of the 
release of G1-ITEGE and ADAMTS5 into the media of articular 
chondrocyte cultures. Human articular chondrocytes were 
cultured in monolayer in the absence (−) or presence (+) of 10 
ng/ml IL-1β and treated with 0 to 10 µM kartogenin (KGN) for 
48 hours (A). Bovine articular chondrocytes were cultured with 
(+) or without (−) 1 ng/mL IL-1β in the presence (+) or absence 
(−) of 10 µM KGN for 48 hours (B, C). The media were collected 
and processed for Western blot analysis (A, B); total RNA was 
isolated for real-time reverse transcription–polymerase chain 
reaction (RT-PCR) (C). KGN treatment alone did not stimulate 
the release of ITEGE while IL-1β treatment did; however, the 
enhanced release of ITEGE was inhibited by co-treatment with 
KGN and IL-1β (A, B). Increasing concentrations of KGN resulted 
in a proportionate decrease in ITEGE released by IL-1β-treated 
human chondrocytes (A). Increased release of ITEGE, ADAMTS4, 
and ADAMTS5 resulted from the treatment with IL-1β; however, 
co-incubation with KGN blocked the stimulated release of ITEGE 
and ADAMTS5, while ADAMTS4 did not show significant change 
(B). Under the same condition, KGN treatment reduced the IL-
1β-induced increase of ADAMTS5 gene expression (C, n = 3; 
*P = 0.010, #P = 0.033).
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Figure 4. Kartogenin decreases CD44 fragmentation in bovine 
articular chondrocytes and in a long culture of human osteoarthritis 
cartilage explants. (A) Bovine articular chondrocytes were 
stimulated with 10 ng/mL IL-1β in the presence or absence of 
10 µM kartogenin (KGN) for 48 hours. Western blot analysis 
of lysates revealed CD44 expression and fragmentation (CD44-
EXT) detected with an anti-cytotail antibody and total β-actin. 
The IL-1β-stimulated fragmentation of CD44 was partially 
blocked when chondrocytes were co-treated with KGN but 
enhanced total CD44 expression persisted. Western blot analysis 
of media showed no G1-ITEGE unless the chondrocytes were 
stimulated with IL-1β, and the release of G1-ITEGE was reduced 
on co-treatment with KGN. Blots shown are representative of 2 
independent experiments. (B) Human osteoarthritic cartilage was 
cultured as explants for 6 weeks in the absence or presence of 10 
µM KGN. Western blot analysis of the directly extracted proteins 
revealed CD44 expression, total β-actin and total ITEGE. A 
decrease in the accumulation of G1-ITEGE in the human cartilage 
treated with KGN was observed accompanied by a decrease of 
CD44 fragmentation (CD44-EXT).
C-terminal fragment in the membrane (CD44-EXT); an 
event that we postulate limits the capacity of the receptor to 
retain HA/aggrecan complexes.29 Stimulation of bovine 
articular chondrocytes with IL-1β resulted in the accumula-
tion of 15 kD and 18 to 20 kD proteolytic fragments of 
CD44 (Fig. 4A). However, incubation of chondrocytes in 
the combined presence of IL-1β and kartogenin reduced the 
production of these CD44 fragments (Fig. 4A). We have 
also observed similar CD44 fragments in detergent extracts 
of intact human osteoarthritic cartilage explants cultured in 
vitro, although the bands are displayed as 15 kD and 25 kD 
CD44-EXT fragments (Fig. 4B). Parallel cartilage explants 
treated for several weeks with kartogenin revealed a 
decrease in the production of CD44 fragments (Fig. 4B). 
This suggests that the sheddase activity responsible for 
CD44 proteolytic cleavage is diminished following the 
application of kartogenin. In the same tissue detergent 
extracts, the accumulation of G1-ITEGE was explored (Fig. 
4B). Again, incubation of the human cartilage explants with 
kartogenin diminished the accumulation of this end-product 
of aggrecanase activity suggesting that kartogenin exhibits 
a generalized anti-catabolic effect.
Kartogenin Stimulates SMAD1 Phosphorylation 
under IL-1β Treatment in Chondrocytes
The effect of kartogenin on the anabolic response of bovine 
and human chondrocytes was studied by evaluating SMAD1 
phosphorylation. As a positive control, BMP7 treatment 
was used as a means to probe for anabolic responsiveness of 
our chondrocyte cultures.33 BMP7 treatment resulted in 
phosphorylation of SMAD1/5/8 in both bovine (Fig. 5A) 
and human (Fig. 5B) chondrocytes as expected. Treatment 
of these chondrocytes with kartogenin alone resulted in no 
activation of SMAD1/5/8 suggesting that kartogenin itself 
cannot directly or via non-canonical cross-talk mechanisms 
activate SMAD1 (Fig. 5A and 5B). However, when the 
same concentration of kartogenin was added to bovine or 
human chondrocytes following IL-1β stimulation, enhanced 
SMAD1 phosphorylation was observed, notably at the 6 
hour timepoint (Fig. 5C and 5D).
Discussion
During osteoarthritis one of the earliest changes observed is 
a loss of aggrecan from the extracellular matrix of cartilage. 
Moreover, this loss is likely initiated within a region near to 
the surface of chondrocytes, termed the pericellular matrix. 
Our laboratory has developed techniques to selectively 
observe and manipulate the glycosaminoglycan-rich pericel-
lular matrix surrounding chondrocytes in vitro. These gel-
like chondrocyte coats represent hyaluronan/aggrecan/link 
protein aggregates bound to the cell surface via the hyaluro-
nan receptor, CD44.35 Thus, we reasoned that the retention 
of these gel coats would represent the first site wherein a 
predicted chondroprotective effect would ever be observed. 
The typical loss of pericellular coats due to IL-1β treatment 
was blocked by co-incubation with kartogenin, while karto-
genin treatment alone did not significantly enhance chon-
drocyte pericellular coat size. In addition, no significant 
changes in the mRNA expression for chondrocyte-specific 
genes, such as collagen II, aggrecan, and Sox9, because of 
kartogenin treatment were observed in either human or 
bovine articular chondrocytes (data not shown). This sug-
gests that kartogenin exerts more of an effect of blocking 
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degradation than by stimulating repair. Significant blocking 
effects of kartogenin were also observed on IL-1β-induced 
reduction in safranin O staining of neocartilage and sulfated 
glycosaminoglycan release from articular cartilage cultured 
as explants. Kartogenin blocked the IL-1β-mediated loss of 
proteoglycans in neocartilages and articular cartilage 
explants as well as but had less effect on stimulating new 
biosynthesis. Thus, corroborating the original kartogenin 
report,20 we observed a chondroprotective effect, namely 
blockage of the cellular responses to catabolic stimulation, 
of kartogenin on chondrocytes and cartilage. On the other 
hand, little effect was seen by kartogenin treatment alone on 
non-cytokine-stimulated articular chondrocytes, either of 
catabolic markers or those related to biosynthesis.
Filamin A, a known actin-binding protein, connects the 
intracellular filamentous network to cell-membrane pro-
teins, and can sequester core-binding factor β (CBFβ) in the 
cytoplasm.36 Additionally, hyaluronan-CD44 interactions 
promote the recruitment of filamin A to lipid raft domains.37 
Kartogenin is reported to bind to filamin A, displacing CBFβ 
from its cytoplasmic binding site; then CBFβ enters the 
nucleus where it binds to the DNA-binding transcription fac-
tor RUNX1.20,40 The CBFβ–RUNX1 complex activates the 
transcription of proteins involved in cartilage differentiation, 
increases the synthesis of components of the cartilage matrix 
(such as collagen type II, aggrecan, and tissue inhibitors of 
metalloproteinases). This mechanism was proposed for the 
chondrogenic effect of kartogenin in the original report.20 
However, on the other hand, CBFβ also acts as a co-activator 
of RUNX2, which is known to play important roles in skel-
etal development, in terms of hypertrophic differentiation in 
growth plates, as well as in osteoarthritis pathology.38-42 
RUNX1 and RUNX2 are regulated differentially, depending 
on the stage of chondrogenic differentiation.42 This might 
explain why kartogenin does not enhance matrix synthesis 
in differentiated adult articular chondrocytes.
In the original report,20 the chondrogenic effect of karto-
genin was demonstrated on primary human mesenchymal 
stem cells or mouse ATDC5 cell lines, both of which can be 
induced to differentiate into chondrocytes by growth factor 
stimulation, including the stimulation by BMPs and other 
members of the TGFbeta superfamily that can signal 
through the SMAD transcriptional modulators. Aggrecan, 
CD44 and HAS-2 genes all exhibit SMAD-binding ele-
ments.33 The effect of kartogenin on the anabolic response 
of human and bovine chondrocytes was studied by western 
blot analyses of SMAD1 phosphorylation. However, the 
effects of kartogenin on the anabolic response of SMAD1 
phosphorylation in response to BMP-7 were only detected 
on chondrocytes activated by IL-1β. These results suggest a 
possible anabolic effect of kartogenin on catabolically- 
activated chondrocytes.
To investigate the mechanism of the chondroprotective 
effect of kartogenin, we focused on the degradation of 
aggrecan. IL-1β stimulated the release of the aggrecan G1 
domain fragment domains terminating with the neoepitope 
Figure 5. Kartogenin stimulates SMAD1 phosphorylation only under IL-1β treatment in articular chondrocytes. The effect of kartogenin 
on the anabolic response of bovine and human chondrocytes was studied by western blot analyses of SMAD1 phosphorylation. Bovine 
(A, C) or human (B, D) chondrocytes were treated with 100 ng/mL BMP7 or 100 µM kartogenin (KGN) for 1 to 6 hours, lysed, and 
Western blots were analyzed. BMP7 treatment resulted in phosphorylation of SMAD1/5/8 as expected, and treatment with KGN 
resulted in no change in SMAD1 phosphorylation (A, B). However, following IL-1β stimulation for up to 24 hours, KGN treatment 
resulted in enhanced SMAD1 phosphorylation, notably at the 6-hour time point (C, D).
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sequence ITEGE. This ITEGE-containing fragment was 
reduced following kartogenin treatment of bovine and 
human articular chondrocytes. Additionally, kartogenin 
decreased aggrecan G1 domain neoepitope ITEGE accumu-
lation in human cartilage explants. These protective effects 
on chondrocytes and cartilage appeared to be due to inhibi-
tion of ADAMTS5, as shown by reduced levels of 
ADAMTS5 mRNA as well as released mature protein.
The mechanism whereby kartogenin affects the retention 
of aggrecan in adult articular cartilage may be mainly by 
blocking degradation of both CD44 and aggrecan, not by 
enhanced synthesis. These effects of kartogenin are signifi-
cant after activation of chondrocytic chondrolysis (e.g., by 
IL-1, TNFα, or oncostatin M). We have shown previously 
that proteolytic cleavage of CD44 occurs in articular chon-
drocytes. Moreover, this degradation is pronounced in cells 
from patients undergoing total knee replacement or in vitro 
models such as IL-1 exposure, used to mimic osteoarthri-
tis.29 This initial cleavage of CD44 occurs by the action of 
membrane-type metalloproteases such as membrane type I 
(MT1-MMP), ADAM17 or ADAM10 and could be blocked 
by inhibitors of matrix metalloproteinases such as GM6001. 
The residual C-terminal fragment of CD44 (CD44-EXT) 
then becomes a substrate for intramembranous cleavage by 
γ-secretase, releasing an intracellular domain fragment of 
CD44 into the cytoplasm. In this study, kartogenin blocked 
the proteolytic cleavage of CD44 suggesting that many of 
the proteolytic events (MT1-MMP, ADAMTS5, etc.) likely 
share a common regulatory pathway. Kartogenin treatment 
was somewhat effective in blocking the IL-1β-induced 
increased expression of ADAMTS-5 mRNA and protein; as 
well, kartogenin treatment resulted in a reduction in the 
aggrecan G1-ITEGE neoepitope generated in IL-1β-
activated cultures. Therefore, likely mechanisms of karto-
genin activity include effects on aggrecanases, as well as 
the proteolytic cleavage of CD44.
In conclusion, these studies provide novel information 
on the chondroprotective function of kartogenin in adult 
articular cartilage. This effect of kartogenin is significant 
after activation of chondrocytic chondrolysis which may 
occur following disruption of homeostasis maintained by 
hyaluronan-CD44 interactions.
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